Trinity Biotech ( (TRIB) ) has released a notification of late filing.
Trinity Biotech has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the transition of the Chief Financial Officer role, as the former CFO stepped down and an interim CFO took over on April 11, 2025. The company is working diligently to finalize the necessary financial information and expects to file the report within fifteen days following the original due date. Financially, Trinity Biotech anticipates reporting revenues between $60.0 million and $62.0 million, with a net loss ranging from $29.0 million to $31.0 million for 2024. This reflects a slight increase in revenue but a higher net loss compared to 2023. The company remains committed to compliance, as indicated by the signature of Interim CFO Susan O’Connor on the notification.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.
Trinity Biotech’s stock score is low due to significant financial difficulties, including declining revenues and high leverage. Technical indicators suggest a downtrend with potential overbought conditions. Although the earnings call noted some improvements, persistent challenges and a negative valuation outlook weigh heavily on the overall score.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
YTD Price Performance: -20.11%
Average Trading Volume: 125,177
Technical Sentiment Signal: Buy
Current Market Cap: $8.64M
See more data about TRIB stock on TipRanks’ Stock Analysis page.